SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Jeff Collins will participate on a panel titled "Funding Innovation, Cross-Border Investments and M&A Trends" at the US India BioPharma & Healthcare Summit in Cambridge, MA
News | 05. 14. 2009
